Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01

BACKGROUND: VRC01 is a human IgG1 broadly neutralizing antibody (bnAb) that binds to the HIV-1 envelope glycoprotein. It is being evaluated in two ongoing efficacy trials, the first assessment of a passively-administered bnAb for HIV-1 prevention. HVTN 104 was a Phase 1 trial of VRC01. SETTING: We m...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Acquir Immune Defic Syndr
Egile Nagusiak: Huang, Yunda, Zhang, Yuanyuan, Bailer, Robert, Grunenberg, Nicole, Carpp, Lindsay N., Seaton, Kelly, Mayer, Kenneth H., Ledgerwood, Julie, Corey, Lawrence, Mascola, John, Montefiori, David, Gilbert, Peter B.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7594341/
https://ncbi.nlm.nih.gov/pubmed/31855881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000002272
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak